Vukorepa Gorana, Deveđija Sabina, Crnjaković Miljenko, Karakaš Mirna, Ćuk Željka
Department of Neurology, University Hospital Dubrava, Zagreb, Croatia.
Turk J Emerg Med. 2020 May 27;20(2):90-92. doi: 10.4103/2452-2473.285015. eCollection 2020 Apr-Jun.
Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial National Institutes of Health Stroke Scale (NIHSS) of 8. Dabigatran was reversed with idarucizumab, and intravenous tissue-type plasminogen activator (IV-tPA) was administrated beginning 4 h and 28 min after the symptom onset. The patient was discharged with an NIHSS of 1. Our case is an additional proof of safety and efficiency of idarucizumab in the clinical setting of ischemic stroke before the administration of IV-tPA.
达比加群是一种直接口服抗凝剂，广泛用于预防心房颤动患者的中风。我们报告了一例80岁的中风患者，该患者因永久性心房颤动服用达比加群，初始美国国立卫生研究院卒中量表（NIHSS）评分为8分。使用依达赛珠单抗逆转达比加群的作用，并在症状发作后4小时28分钟开始静脉注射组织型纤溶酶原激活剂（IV-tPA）。患者出院时NIHSS评分为1分。我们的病例进一步证明了依达赛珠单抗在缺血性中风临床环境中、在给予IV-tPA之前的安全性和有效性。
